Britain and America have signed a significant commercial pact that will guarantee no import taxes on British pharmaceutical products being sold in the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to raise funding on drugs through the NHS. This commitment guarantees that duties on these vital products will remain at zero for a period of the next three years.
This deal comes after previous warnings to dramatically increase duties on patented drug products, with increases discussed up to double the cost.
"This arrangement between the UK bolsters the international landscape for new treatments and brings long-overdue equity to transatlantic pharmaceutical trade," an announcement said.
Economic Significance
Medicines constitute one of the the United Kingdom's biggest export categories to the United States, which is clearly the primary buyer for large British pharmaceutical firms.
Trade data reveal that in the one-year period leading up to last September, the UK exported medicines worth over eleven billion pounds to the US. This amount made up 17.4% of all goods exports in that timeframe.
"This deal safeguards work, increases funding and paves the way for the UK to emerge as a worldwide center for medical research," a government official stated.
Specific NHS Changes
The deal entails several specific commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it deems new treatments to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a goal to double overall health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The percentage drug companies must refund to the NHS to prevent overspending will be restricted at 15%. Last year, repayments exceeded 20%.
Industry Background
This agreement follows a long-running tension between the drug companies and the UK government over medicine costs and regulatory access.
This friction were exacerbated by arguments that American consumers were charged significantly more for the same drugs than consumers in the Britain and the EU.
In recent months, several significant manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been pledged toward American operations.
A senior figure stated that the NHS had to increase expenditure on treatments, noting that its spending on drugs had shrunk as a percentage of its resources over the previous ten-year period.
